{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T05:22:30Z","timestamp":1762320150925,"version":"build-2065373602"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","award":["00000313"],"award-info":[{"award-number":["00000313"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020402","name":"Y-mAbs Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020402","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Breast Cancer"],"DOI":"10.1038\/s41523-025-00843-7","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T03:52:10Z","timestamp":1762314730000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting GD2 with naxitamab overcomes GD3 synthase-driven immune suppression in triple-negative breast cancer"],"prefix":"10.1038","volume":"11","author":[{"given":"Vivek","family":"Anand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bolutyfe","family":"Oderinde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anudishi","family":"Tyagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"Borgman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Andreeff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. Lokesh","family":"Battula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"843_CR1","unstructured":"Menon, G., Alkabban, F. M. & Ferguson, T. Breast Cancer, in StatPearls 2024, StatPearls Publishing Copyright\u00a9, (StatPearls Publishing LLC: Treasure Island, FL, USA, 2025)."},{"key":"843_CR2","unstructured":"American Cancer Society, Breast Cancer Facts & Figures 2022-2024. Atlanta: American Cancer Society (2022)."},{"key":"843_CR3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1148\/radiol.2021203476","volume":"299","author":"RE Hendrick","year":"2021","unstructured":"Hendrick, R. E., Helvie, M. A. & Monticciolo, D. L. Breast cancer mortality rates have stopped declining in U.S. women younger than 40 years. Radiology 299, 143\u2013149 (2021).","journal-title":"Radiology"},{"key":"843_CR4","first-page":"409","volume":"72","author":"KD Miller","year":"2022","unstructured":"Miller, K. D. et al. Cancer treatment and survivorship statistics. CA Cancer J. Clin. 72, 409\u2013436 (2022).","journal-title":"CA Cancer J. Clin."},{"key":"843_CR5","first-page":"438","volume":"69","author":"CE DeSantis","year":"2019","unstructured":"DeSantis, C. E. et al. Breast cancer statistics, 2019. CA Cancer J. Clin. 69, 438\u2013451 (2019).","journal-title":"CA Cancer J. Clin."},{"key":"843_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","volume":"19","author":"G Bianchini","year":"2022","unstructured":"Bianchini, G. et al. Treatment landscape of triple-negative breast cancer\u2014expanded options, evolving needs. Nat. Rev. Clin. Oncol. 19, 91\u2013113 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"843_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","volume":"15","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. Recent advances in therapeutic strategies for triple-negative breast cancer. J. Hematol. Oncol. 15, 121 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"843_CR8","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.canlet.2020.10.016","volume":"497","author":"X Bai","year":"2021","unstructured":"Bai, X. et al. Triple-negative breast cancer therapeutic resistance: Where is the Achilles\u2019 heel? Cancer Lett. 497, 100\u2013111 (2021).","journal-title":"Cancer Lett."},{"key":"843_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3233\/BD-2010-0319","volume":"32","author":"GL Gierach","year":"2010","unstructured":"Gierach, G. L., Burke, A. & Anderson, W. F. Epidemiology of triple negative breast cancers. Breast Dis. 32, 5\u201324 (2010).","journal-title":"Breast Dis."},{"key":"843_CR10","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/s41416-021-01328-7","volume":"125","author":"F L\u00fc\u00f6nd","year":"2021","unstructured":"L\u00fc\u00f6nd, F., Tiede, S. & Christofori, G. Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression. Br. J. Cancer 125, 164\u2013175 (2021).","journal-title":"Br. J. Cancer"},{"key":"843_CR11","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.ajpath.2013.08.002","volume":"183","author":"AG Rivenbark","year":"2013","unstructured":"Rivenbark, A. G., O\u2019Connor, S. M. & Coleman, W. B. Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine. Am. J. Pathol. 183, 1113\u20131124 (2013).","journal-title":"Am. J. Pathol."},{"key":"843_CR12","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747\u201352 (2000).","journal-title":"Nature"},{"key":"843_CR13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1146\/annurev.med.58.062105.204854","volume":"58","author":"P Dalerba","year":"2007","unstructured":"Dalerba, P., Cho, R. W. & Clarke, M. F. Cancer stem cells: models and concepts. Annu. Rev. Med 58, 267\u201384 (2007).","journal-title":"Annu. Rev. Med"},{"key":"843_CR14","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1083\/jcb.201202014","volume":"198","author":"I Baccelli","year":"2012","unstructured":"Baccelli, I. & Trumpp, A. The evolving concept of cancer and metastasis stem cells. J. Cell Biol. 198, 281\u201393 (2012).","journal-title":"J. Cell Biol."},{"key":"843_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04116-6","volume":"12","author":"K Chen","year":"2021","unstructured":"Chen, K. et al. The metabolic flexibility of quiescent CSC: implications for chemotherapy resistance. Cell Death Dis. 12, 835 (2021).","journal-title":"Cell Death Dis."},{"key":"843_CR16","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s13287-022-02904-1","volume":"13","author":"F Ju","year":"2022","unstructured":"Ju, F. et al. Characteristics of the cancer stem cell niche and therapeutic strategies. Stem Cell Res. Ther. 13, 233 (2022).","journal-title":"Stem Cell Res. Ther."},{"key":"843_CR17","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s11523-017-0508-3","volume":"12","author":"JD Lathia","year":"2017","unstructured":"Lathia, J. D. & Liu, H. Overview of cancer stem cells and stemness for community oncologists. Target. Oncol. 12, 387\u2013399 (2017).","journal-title":"Target. Oncol."},{"key":"843_CR18","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1073\/pnas.0530291100","volume":"100","author":"M Al-Hajj","year":"2003","unstructured":"Al-Hajj, M. et al. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 100, 3983\u20138 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"843_CR19","doi-asserted-by":"publisher","first-page":"1740936","DOI":"10.1155\/2016\/1740936","volume":"2016","author":"W Chen","year":"2016","unstructured":"Chen, W. et al. Cancer stem cell quiescence and plasticity as major challenges in cancer therapy. Stem Cells Int. 2016, 1740936 (2016).","journal-title":"Stem Cells Int."},{"key":"843_CR20","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1073\/pnas.0830967100","volume":"100","author":"JE Dick","year":"2003","unstructured":"Dick, J. E. Breast cancer stem cells revealed. Proc. Natl. Acad. Sci. USA 100, 3547\u20139 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"843_CR21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41392-020-0110-5","volume":"5","author":"L Yang","year":"2020","unstructured":"Yang, L. et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct. Target Ther. 5, 8 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"843_CR22","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1172\/JCI59735","volume":"122","author":"VL Battula","year":"2012","unstructured":"Battula, V. L. et al. Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J. Clin. Investig. 122, 2066\u201378 (2012).","journal-title":"J. Clin. Investig."},{"key":"843_CR23","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1158\/1535-7163.MCT-18-0399","volume":"17","author":"K Nguyen","year":"2018","unstructured":"Nguyen, K. et al. ST8SIA1 regulates tumor growth and metastasis in TNBC by activating the FAK-AKT-mTOR signaling pathway. Mol. Cancer Ther. 17, 2689\u20132701 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"843_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/nyas.14700","volume":"1508","author":"C Shao","year":"2022","unstructured":"Shao, C. et al. Ganglioside GD2: a novel therapeutic target in triple-negative breast cancer. Ann. N. Y Acad. Sci. 1508, 35\u201353 (2022).","journal-title":"Ann. N. Y Acad. Sci."},{"key":"843_CR25","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41416-021-01636-y","volume":"126","author":"A Jaggupilli","year":"2022","unstructured":"Jaggupilli, A. et al. Metabolic stress induces GD2(+) cancer stem cell-like phenotype in triple-negative breast cancer. Br. J. Cancer 126, 615\u2013627 (2022).","journal-title":"Br. J. Cancer"},{"key":"843_CR26","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1038\/onc.2014.245","volume":"34","author":"TR Sarkar","year":"2015","unstructured":"Sarkar, T. R. et al. GD3 synthase regulates epithelial-mesenchymal transition and metastasis in breast cancer. Oncogene 34, 2958\u201367 (2015).","journal-title":"Oncogene"},{"key":"843_CR27","doi-asserted-by":"crossref","unstructured":"Ly, S. et al. Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2(+) breast cancer stem-like cells. J. Immunother Cancer 9, e001197 (2021).","DOI":"10.1136\/jitc-2020-001197"},{"key":"843_CR28","first-page":"10","volume":"79","author":"JW Chu","year":"1993","unstructured":"Chu, J. W. & Sharom, F. J. Gangliosides inhibit T-lymphocyte proliferation by preventing the interaction of interleukin-2 with its cell surface receptors. Immunology 79, 10\u20137 (1993).","journal-title":"Immunology"},{"key":"843_CR29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.cellimm.2018.01.014","volume":"325","author":"B Dillinger","year":"2018","unstructured":"Dillinger, B. et al. IFN-gamma and tumor gangliosides: implications for the tumor microenvironment. Cell Immunol. 325, 33\u201340 (2018).","journal-title":"Cell Immunol."},{"key":"843_CR30","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/j.1365-2567.2010.03348.x","volume":"132","author":"A Jales","year":"2011","unstructured":"Jales, A. et al. Ganglioside-exposed dendritic cells inhibit T-cell effector function by promoting regulatory cell activity. Immunology 132, 134\u201343 (2011).","journal-title":"Immunology"},{"key":"843_CR31","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1172\/JCI111631","volume":"74","author":"S Ladisch","year":"1984","unstructured":"Ladisch, S. et al. Modulation of the immune response by gangliosides. Inhibition of adherent monocyte accessory function in vitro. J. Clin. Investig. 74, 2074\u201381 (1984).","journal-title":"J. Clin. Investig."},{"key":"843_CR32","doi-asserted-by":"publisher","first-page":"971","DOI":"10.4049\/jimmunol.136.3.971","volume":"136","author":"RJ Robb","year":"1986","unstructured":"Robb, R. J. The suppressive effect of gangliosides upon IL 2-dependent proliferation as a function of inhibition of IL 2-receptor association. J. Immunol. 136, 971\u20136 (1986).","journal-title":"J. Immunol."},{"key":"843_CR33","doi-asserted-by":"publisher","first-page":"1282572","DOI":"10.3389\/fphar.2023.1282572","volume":"14","author":"A Sarkar","year":"2023","unstructured":"Sarkar, A., Banerjee, S. & Biswas, K. Multi-dimensional role of gangliosides in modulating cancer hallmarks and their prospects in targeted cancer therapy. Front. Pharm. 14, 1282572 (2023).","journal-title":"Front. Pharm."},{"key":"843_CR34","doi-asserted-by":"crossref","unstructured":"Schengrund, C. L. The ying and yang of ganglioside function in cancer. Cancers 22, 5362 (2023).","DOI":"10.3390\/cancers15225362"},{"key":"843_CR35","first-page":"363","volume":"61","author":"GV Shurin","year":"2001","unstructured":"Shurin, G. V. et al. Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res. 61, 363\u20139 (2001).","journal-title":"Cancer Res."},{"key":"843_CR36","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s10555-023-10108-z","volume":"42","author":"I van der Haar Avila","year":"2023","unstructured":"van der Haar Avila, I., Windhouwer, B. & van Vliet, S. J. Current state-of-the-art on ganglioside-mediated immune modulation in the tumor microenvironment. Cancer Metastasis Rev. 42, 941\u2013958 (2023).","journal-title":"Cancer Metastasis Rev."},{"key":"843_CR37","doi-asserted-by":"crossref","unstructured":"Bobowski-G, M., Harduin, L. A. & Delannoy, P. ST8 Alpha-N-Acetyl-Neuraminide Alpha-2,8-Sialyltransferase 1 (ST8SIA1), (eds Taniguchi N. et al.) 767\u2013780 (Springer Japan: Tokyo, 2014).","DOI":"10.1007\/978-4-431-54240-7_118"},{"key":"843_CR38","doi-asserted-by":"crossref","unstructured":"Kasprowicz, A. et al. Role of GD3 synthase ST8Sia I in cancers. Cancers 14, 1299 (2022).","DOI":"10.3390\/cancers14051299"},{"key":"843_CR39","doi-asserted-by":"crossref","unstructured":"Anand, V. et al. GD3 synthase drives resistance to p53-induced apoptosis in breast cancer by modulating mitochondrial function. Oncogene 44, 2646\u20132661 (2025).","DOI":"10.1038\/s41388-025-03432-x"},{"key":"843_CR40","doi-asserted-by":"publisher","first-page":"PO2-24-08","DOI":"10.1158\/1538-7445.SABCS23-PO2-24-08","volume":"84","author":"V Anand","year":"2024","unstructured":"Anand, V. et al. Abstract PO2-24-08: GD3 synthase is a master regulator of wild-type p53\u2013mediated apoptosis and mutant p53\u2013mediated tumorigenesis. Cancer Res. 84, PO2-24-08\u2013PO2-24-08 (2024).","journal-title":"Cancer Res."},{"key":"843_CR41","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/ijc.2910440127","volume":"44","author":"H Bernhard","year":"1989","unstructured":"Bernhard, H., Meyer zum Buschenfelde, K. H. & Dippold, W. G. Ganglioside GD3 shedding by human malignant melanoma cells. Int. J. Cancer 44, 155\u201360 (1989).","journal-title":"Int. J. Cancer"},{"key":"843_CR42","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/ijc.2910530614","volume":"53","author":"J Portoukalian","year":"1993","unstructured":"Portoukalian, J. et al. Shedding of GD2 ganglioside in patients with retinoblastoma. Int. J. Cancer 53, 948\u201351 (1993).","journal-title":"Int. J. Cancer"},{"key":"843_CR43","first-page":"3808","volume":"43","author":"S Ladisch","year":"1983","unstructured":"Ladisch, S. et al. Shedding and immunoregulatory activity of YAC-1 lymphoma cell gangliosides. Cancer Res. 43, 3808\u201313 (1983).","journal-title":"Cancer Res."},{"key":"843_CR44","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.4049\/jimmunol.163.7.3718","volume":"163","author":"R McKallip","year":"1999","unstructured":"McKallip, R., Li, R. & Ladisch, S. Tumor gangliosides inhibit the tumor-specific immune response1. J. Immunol. 163, 3718\u20133726 (1999).","journal-title":"J. Immunol."},{"key":"843_CR45","doi-asserted-by":"publisher","first-page":"4425","DOI":"10.4049\/jimmunol.180.7.4425","volume":"180","author":"W Shen","year":"2008","unstructured":"Shen, W. et al. Inhibition of TLR activation and up-regulation of IL-1R-associated kinase-M expression by exogenous gangliosides1. J. Immunol. 180, 4425\u20134432 (2008).","journal-title":"J. Immunol."},{"key":"843_CR46","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1365-2567.2007.02760.x","volume":"123","author":"JE Park","year":"2008","unstructured":"Park, J. E. et al. Fine specificity of natural killer T cells against GD3 ganglioside and identification of GM3 as an inhibitory natural killer T-cell ligand. Immunology 123, 145\u201355 (2008).","journal-title":"Immunology"},{"key":"843_CR47","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1158\/1538-7445.AM2024-2672","volume":"84","author":"B Oderinde","year":"2024","unstructured":"Oderinde, B. et al. Abstract 2672: GD3 synthase (ST8SIA1) is a key immunomodulator in GD2+ breast cancer cells. Cancer Res. 84, 2672\u20132672 (2024).","journal-title":"Cancer Res."},{"key":"843_CR48","doi-asserted-by":"publisher","first-page":"P5-06-10","DOI":"10.1158\/1538-7445.SABCS21-P5-06-10","volume":"82","author":"V Anand","year":"2022","unstructured":"Anand, V. et al. Abstract P5-06-10: tumor microenvironment modulates ganglioside expression leading to immunosuppression in triple negative breast cancer. Cancer Res. 82, P5-06-10\u2013P5-06-10 (2022).","journal-title":"Cancer Res."},{"key":"843_CR49","doi-asserted-by":"publisher","first-page":"1076862","DOI":"10.3389\/fcell.2023.1076862","volume":"11","author":"S Cao","year":"2023","unstructured":"Cao, S. et al. The biological role and immunotherapy of gangliosides and GD3 synthase in cancers. Front. Cell Dev. Biol. 11, 1076862 (2023).","journal-title":"Front. Cell Dev. Biol."},{"key":"843_CR50","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u20134 (2012).","journal-title":"Cancer Discov."},{"key":"843_CR51","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s40265-021-01467-4","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham, A. Naxitamab: first approval. Drugs 81, 291\u2013296 (2021).","journal-title":"Drugs"},{"key":"843_CR52","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1358\/dot.2021.57.11.3343691","volume":"57","author":"LR Slatnick","year":"2021","unstructured":"Slatnick, L. R. et al. Naxitamab: a humanized anti-glycolipid disialoganglioside (anti-GD2) monoclonal antibody for treatment of neuroblastoma. Drugs Today 57, 677\u2013688 (2021).","journal-title":"Drugs Today"},{"key":"843_CR53","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41378-023-00616-x","volume":"9","author":"S Abizanda-Campo","year":"2023","unstructured":"Abizanda-Campo, S. et al. Microphysiological systems for solid tumor immunotherapy: opportunities and challenges. Microsyst. Nanoeng. 9, 154 (2023).","journal-title":"Microsyst. Nanoeng."},{"key":"843_CR54","doi-asserted-by":"publisher","first-page":"656364","DOI":"10.3389\/fimmu.2021.656364","volume":"12","author":"K Khalaf","year":"2021","unstructured":"Khalaf, K. et al. Aspects of the tumor microenvironment involved in immune resistance and drug resistance. Front. Immunol. 12, 656364 (2021).","journal-title":"Front. Immunol."},{"key":"843_CR55","doi-asserted-by":"publisher","first-page":"868695","DOI":"10.3389\/fphar.2022.868695","volume":"13","author":"SK Kim","year":"2022","unstructured":"Kim, S. K. & Cho, S. W. The evasion mechanisms of cancer immunity and drug intervention in the tumor microenvironment. Front. Pharm. 13, 868695 (2022).","journal-title":"Front. Pharm."},{"key":"843_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17670-y","volume":"11","author":"C Robert","year":"2020","unstructured":"Robert, C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat. Commun. 11, 3801 (2020).","journal-title":"Nat. Commun."},{"key":"843_CR57","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1158\/0008-5472.CAN-20-2990","volume":"81","author":"NR Anderson","year":"2021","unstructured":"Anderson, N. R. et al. Macrophage-based approaches for cancer immunotherapy. Cancer Res. 81, 1201\u20131208 (2021).","journal-title":"Cancer Res."},{"key":"843_CR58","doi-asserted-by":"publisher","first-page":"948098","DOI":"10.1155\/2012\/948098","volume":"2012","author":"NB Hao","year":"2012","unstructured":"Hao, N. B. et al. Macrophages in tumor microenvironments and the progression of tumors. Clin. Dev. Immunol. 2012, 948098 (2012).","journal-title":"Clin. Dev. Immunol."},{"key":"843_CR59","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","volume":"124","author":"H Raskov","year":"2021","unstructured":"Raskov, H. et al. Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. Br. J. Cancer 124, 359\u2013367 (2021).","journal-title":"Br. J. Cancer"},{"key":"843_CR60","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.molimm.2022.02.015","volume":"144","author":"W Zhang","year":"2022","unstructured":"Zhang, W., Zhao, Z. & Li, F. Natural killer cell dysfunction in cancer and new strategies to utilize NK cell potential for cancer immunotherapy. Mol. Immunol. 144, 58\u201370 (2022).","journal-title":"Mol. Immunol."},{"key":"843_CR61","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1172\/JCI65899","volume":"124","author":"C Jandus","year":"2014","unstructured":"Jandus, C. et al. Interactions between Siglec-7\/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. J. Clin. Investig. 124, 1810\u201320 (2014).","journal-title":"J. Clin. Investig."},{"key":"843_CR62","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41591-021-01625-x","volume":"28","author":"J Theruvath","year":"2022","unstructured":"Theruvath, J. et al. Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication. Nat. Med. 28, 333\u2013344 (2022).","journal-title":"Nat. Med."},{"key":"843_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"L Yin","year":"2020","unstructured":"Yin, L. et al. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 22, 61 (2020).","journal-title":"Breast Cancer Res."},{"key":"843_CR64","doi-asserted-by":"publisher","first-page":"73329","DOI":"10.18632\/oncotarget.20274","volume":"8","author":"F Shao","year":"2017","unstructured":"Shao, F., Sun, H. & Deng, C. X. Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype. Oncotarget 8, 73329\u201373344 (2017).","journal-title":"Oncotarget"},{"key":"843_CR65","first-page":"321","volume":"4","author":"N Fultang","year":"2021","unstructured":"Fultang, N., Chakraborty, M. & Peethambaran, B. Regulation of cancer stem cells in triple negative breast cancer. Cancer Drug Resist. 4, 321\u2013342 (2021).","journal-title":"Cancer Drug Resist."},{"key":"843_CR66","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1053\/j.seminoncol.2010.09.001","volume":"37","author":"MK Callahan","year":"2010","unstructured":"Callahan, M. K., Wolchok, J. D. & Allison, J. P. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin. Oncol. 37, 473\u201384 (2010).","journal-title":"Semin. Oncol."},{"key":"843_CR67","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001014","volume":"8","author":"T Maruhashi","year":"2020","unstructured":"Maruhashi, T. et al. LAG-3: from molecular functions to clinical applications. J. Immunother. Cancer 8, e001014 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"843_CR68","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","volume":"20","author":"JM Taube","year":"2014","unstructured":"Taube, J. M. et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti\u2013PD\u20131 therapy. Clin. Cancer Res. 20, 5064\u20135074 (2014).","journal-title":"Clin. Cancer Res."},{"key":"843_CR69","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1186\/s13046-022-02523-x","volume":"41","author":"YL Sha","year":"2022","unstructured":"Sha, Y. L. et al. B3GALT4 remodels the tumor microenvironment through GD2-mediated lipid raft formation and the c-met\/AKT\/mTOR\/IRF-1 axis in neuroblastoma. J. Exp. Clin. Cancer Res. 41, 314 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"843_CR70","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.febslet.2013.11.030","volume":"588","author":"M Ahmed","year":"2014","unstructured":"Ahmed, M. & Cheung, N. K. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. FEBS Lett. 588, 288\u201397 (2014).","journal-title":"FEBS Lett."},{"key":"843_CR71","doi-asserted-by":"publisher","first-page":"e63359","DOI":"10.1371\/journal.pone.0063359","volume":"8","author":"M Ahmed","year":"2013","unstructured":"Ahmed, M. et al. In silico driven redesign of a clinically relevant antibody for the treatment of GD2 positive tumors. PLoS ONE 8, e63359 (2013).","journal-title":"PLoS ONE"},{"key":"843_CR72","doi-asserted-by":"crossref","unstructured":"Ahmed, M., Hu, J. & Cheung, N. K. Structure based refinement of a humanized monoclonal antibody that targets tumor antigen disialoganglioside GD2. Front. Immunol. 5, 372 (2014).","DOI":"10.3389\/fimmu.2014.00372"},{"key":"843_CR73","doi-asserted-by":"crossref","unstructured":"Somanchi, S. S. et al. Expansion, purification, and functional assessment of human peripheral blood NK cells. J. Vis. Exp. 2, 2540 (2011).","DOI":"10.3791\/2540-v"}],"container-title":["npj Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41523-025-00843-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-025-00843-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-025-00843-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T05:05:59Z","timestamp":1762319159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41523-025-00843-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["843"],"URL":"https:\/\/doi.org\/10.1038\/s41523-025-00843-7","relation":{},"ISSN":["2374-4677"],"issn-type":[{"type":"electronic","value":"2374-4677"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"24 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Authors V.L.B. and M.A. hold US Patent Number US 9846160 B2, titled \u201cGanglioside GD2 as a marker and target on cancer stem cells.\u201d The authors declare no other Competing Financial or Non-Financial Interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"120"}}